The widespread expression observed in our study of the SEMA7A, SEMA4D, ADAM8, and ADAMTS10, depending on the mutational landscape of the KRAS, NRAS, BRAF, PIK3CA, and AKT genes, and the MSI status, along with the significant immune processes within CRC TME, in which these proteins appear to be involved, indicates that SEMA7A, SEMA4D, ADAM8, and ADAMTS10 may be considered as promising subjects for further analysis in cell models, other in silico analyses, or animal model studies, and also as potential therapeutic targets in CRC. This evidence concerns the gene AKT1 and colorectal carcinoma.